J. Brown and M. O’Donnell and ARNP E. Brown will assist in the recruitment of patients from the Department of PROTOCOL #1 Lubaroff, page 14 Urology, Dr. Vaena from Internal Medicine, and Dr. Smith from Radiation Oncology. Additional recruitment of patients will occur through a referral collaboration with Mercy Medical Center, Des Moines, IA (Hereafter referred to as DMMCC). Once accrual has been completed, no further recruitment methods will be utilized. A physician from outside the UIHC or IC VAHCS may inform patients of the study. If a patient expresses interest in learning more about the trial , the physician will provide him with contact information for the clinical trial team. When a patient contacts the clinical trial team, a member of the trial team will briefly describe the study and request the patient’s mailing address in order to mail him a copy of the study informed consent form. After the patient has had time to become familiar with the study and discuss it with his family, a member of the research team will follow up with a telephone call to discuss the study and answer any questions the patient may have. Of particular importance is the patient’s understanding that he will be assigned to one of two arms in the protocol, vaccine alone or androgen deprivation therapy followed by vaccine. At this time, if the patient is still interested in participating, he will be asked to provide verbal consent to allow the research team to review information from his medical record to evaluate his eligibility for the trial. The researcher will document the verbal consent process in the research file, and will contact the patient’s physician to request the medical record for review. The patient will be required to sign a HIPAA privacy form and a Release of Medical Information form at his physician’s office prior to the physician releasing his records to the research team. After reviewing the relevant portions of the medical record, a member of the research team will again contact the patient. Eligible individuals will be scheduled for a visit to the UIHC or IC VAHCS to undergo additional eligibility testing. At that visit, informed consent for participation in the clinical trial will be obtained. The subject will then be further evaluated for study eligibility through a medical history and physical exam, blood tests, and scans. Final determination of eligibility will occur at a weekly meeting of the clinical trial team.